Assessment tool for hospital admissions related to medications: development and validation in older patients.
Assessment tool
Drug-related problems
Elderly
Hospital admissions
Medication-related admissions
Sweden
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
09
06
2018
accepted:
13
12
2018
pubmed:
27
12
2018
medline:
4
6
2019
entrez:
27
12
2018
Statut:
ppublish
Résumé
Background Medication-related hospital admissions (MRAs) are frequently used to measure outcomes in studies involving medication reviews. The process of identifying MRAs is subjective and time-consuming, and practical, validated alternatives are required. Objective The aim of this study was to develop and validate a practical tool to identify MRAs. Setting Uppsala University Hospital, Sweden. Method We reviewed existing literature on methods to identify MRAs. The tool AT-HARM10 was developed using an iterative process including content validity and feasibility testing. The tool's inter-rater reliability (IRR) and criterion-related validity (CRV) were assessed: four pairs of either final-year undergraduate or postgraduate pharmacy students applied the tool to one of two batches of 50 older patients' hospital admissions. Assessment of the same 100 admissions by two experienced clinicians acted as gold standard. Main outcome measure Cohen's and Fleiss' kappa for IRR, and sensitivity, specificity, and positive and negative predictive value for CRV. Results AT-HARM10 consists of ten closed questions to distinguish between admissions that are unlikely to be and those that are possibly medication-related. The IRR was moderate to substantial (Cohen's kappa values were 0.45-0.75 and Fleiss' kappa values were 0.46 and 0.58). The sensitivity and specificity values were 70/86% and 74/70%, positive and negative predictive values were 73/74% and 71/83% respectively. Both AT-HARM10 and the gold standard identified approximately 50% of the admissions as MRAs. Conclusion AT-HARM10 has been developed as a practical tool to identify MRAs and the tool is valid for use in older patients by final-year undergraduate and postgraduate pharmacy students.
Identifiants
pubmed: 30585296
doi: 10.1007/s11096-018-0768-8
pii: 10.1007/s11096-018-0768-8
pmc: PMC6394508
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
198-206Références
Intern Med J. 2001 May-Jun;31(4):199-205
pubmed: 11456032
Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):65-72
pubmed: 11998554
Ann Pharmacother. 2002 Jul-Aug;36(7-8):1238-48
pubmed: 12086559
Eur J Clin Pharmacol. 2002 Jul;58(4):285-91
pubmed: 12136375
Qual Saf Health Care. 2003 Aug;12(4):280-5
pubmed: 12897361
J Intern Med. 2004 Jun;255(6):653-63
pubmed: 15147529
BMJ. 2004 Jul 3;329(7456):15-9
pubmed: 15231615
Br J Clin Pharmacol. 1992 Jan;33(1):61-8
pubmed: 1540492
Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):212-7
pubmed: 16445597
Br J Clin Pharmacol. 2007 Feb;63(2):136-47
pubmed: 16803468
Ther Clin Risk Manag. 2005 Mar;1(1):39-48
pubmed: 18360542
Arch Intern Med. 2008 Sep 22;168(17):1890-6
pubmed: 18809816
Eur J Intern Med. 2008 Nov;19(7):505-10
pubmed: 19013378
Arch Intern Med. 2009 May 11;169(9):894-900
pubmed: 19433702
Drugs Aging. 2009;26(11):951-61
pubmed: 19848440
J Nutr Health Aging. 2010 Jun;14(6):477-82
pubmed: 20617292
Br J Clin Pharmacol. 2010 Nov;70(5):749-55
pubmed: 21039769
BMC Health Serv Res. 2011 Jan 07;11:4
pubmed: 21214918
Eur J Clin Pharmacol. 2011 Jul;67(7):741-52
pubmed: 21318595
J Pharmacol Pharmacother. 2011 Jan;2(1):17-20
pubmed: 21701641
J Am Geriatr Soc. 2012 Jan;60(1):34-41
pubmed: 22150441
PLoS One. 2011;6(12):e28096
pubmed: 22194808
Drug Saf. 2012 Mar 1;35(3):245-59
pubmed: 22339574
J Gerontol A Biol Sci Med Sci. 2012 Aug;67(8):867-74
pubmed: 22389461
DICP. 1990 Nov;24(11):1093-7
pubmed: 2275235
J Am Geriatr Soc. 2013 Jan;61(1):113-21
pubmed: 23252914
Emerg Med J. 2014 Jan;31(1):24-9
pubmed: 23389832
Basic Clin Pharmacol Toxicol. 2013 Jun;112(6):359-73
pubmed: 23506448
Dtsch Arztebl Int. 2013 Mar;110(13):213-9
pubmed: 23596501
Pharmacotherapy. 2013 Aug;33(8):827-37
pubmed: 23686895
PLoS One. 2013 Jun 27;8(6):e66803
pubmed: 23826139
Br J Clin Pharmacol. 2013 Sep;76 Suppl 1:56-68
pubmed: 24007453
Intern Med J. 2014 Jul;44(7):633-8
pubmed: 24750276
Pharmacoepidemiol Drug Saf. 2015 Feb;24(2):176-86
pubmed: 24934134
Saudi Pharm J. 2015 Jan;23(1):1-8
pubmed: 25685036
Eur J Clin Pharmacol. 2017 Jul;73(7):827-835
pubmed: 28391409
Contemp Clin Trials. 2017 Oct;61:126-132
pubmed: 28739539
SAGE Open Med. 2017 Sep 11;5:2050312117730245
pubmed: 28932396
BMC Med. 2018 Feb 13;16(1):21
pubmed: 29433501
Br J Clin Pharmacol. 2018 Nov;84(11):2600-2614
pubmed: 30007041
JAMA. 1979 Aug 17;242(7):623-32
pubmed: 449002
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Age Ageing. 1997 Sep;26(5):375-82
pubmed: 9351482